INTRODUCTION {#s1}
============

Anal squamous cell carcinoma (ASCC) is a rare tumour that accounts for less than 5% of all lower gastrointestinal tract malignancies in Europe \[[@R1]\], but its incidence has increased in the last two decades, especially in HIV men \[[@R2], [@R3]\]. Human papilloma virus (HPV) infection, predominantly by HPV-16, is the main risk factor of these tumours \[[@R4]\]. Other risk factors include anoreceptive intercourse, a high lifetime number of sexual partners, chronic immunosuppression and a history of smoking.

The majority of ASCC are diagnosed at a localized or locally advanced stage, where chemoradiotherapy (CRT) is the standard of care but is associated with a local failure or recurrence in approximately 30% of the patients \[[@R5]\]. A salvage abdominoperineal resection is then indicated but 30 to 60% of operated patients will experience a locoregional and/or metastatic recurrence \[[@R6], [@R7]\]. In these patients with an inoperable locally advanced or metastatic disease, very few treatments are available and their effectiveness is limited. New therapeutic approaches and predictive factors of outcome are required in this context.

A better understanding of molecular markers involved in anal carcinogenesis is required for the identification of new therapeutic targets as well as prognostic and predictive biomarkers. In contrast to other squamous cell carcinomas (SCC) and HPV-related cancers for which several recent large-scale studies have respectively defined the genetic and epigenetic processes involved in oncogenesis \[[@R8]\], the molecular landscape of ASCC is currently not completely characterized. Previously studies have revealed frequent alterations in the PIK3CA/AKT/mTOR pathway, high levels of EGFR expression but few *KRAS* or *BRAF* mutations \[[@R9]--[@R13]\]. Most of these analyses were performed on a limited number of genes or in tumours previously treated by CRT. Only two exome-wide mutational studies are available: the first study of Mouw *et al.* \[[@R14]\] evaluated the impact of CRT on genomic evolution in ASCC recurrences samples (after initial curative CRT) and the second study of Morris KW *et al.* evaluated the genomic evolution in metastatic ASCC samples \[[@R15]\].

To identify potential driver genes and to better understand molecular markers involved in anal squamous carcinogenesis, we performed a whole exome sequencing (WES) analysis focused on a homogeneous cohort of 20 frozen treatment-naive ASCC patients, and identified recurrent somatic alterations and common altered signalling pathways.

RESULTS {#s2}
=======

Patients and tumour characteristics {#s2_1}
-----------------------------------

From a large previous reported cohort of ASCC \[[@R10]\], we identified and included in the present study 20 treatment-naive and fresh frozen tumour tissues for WES analysis. Patients and tumour characteristics were summarized in Table [1](#T1){ref-type="table"}. All tumours were HPV positive, with HPV16 in 19 cases and HPV6-11 in the only HIV positive patient of the series. Most of the tumours (80%) were moderate or well differentiated. All patients except one were treated by CRT or radiotherapy (RT) preceded by surgery or tumour excision in 4 of them.

###### Clinico-pathological features of the 20 treatment-naive ASCC patients

  Clinico-pathological features          Number of patients, *n*
  -------------------------------------- -------------------------
  **Total**                              20
  **Gender**                             
   Female                                16
   Male                                  4
  **Concomitant HIV infection**          
   Yes                                   1
   No                                    19
  **Tumour differentiation**             
   Moderate/Well                         16
   Poor                                  4
  **HPV status**                         
   HPV positive                          20
    genotype 16                          19
    genotype 6--11                       1
   HPV negative                          0
  **Initial tumour stage (AJCC-2010)**   
   I                                     1
   II                                    3
   IIIA                                  8
   IIIB                                  6
   IV\*                                  1
   ND                                    1
  **Initial therapy**                    
   Surgery (tumour excision/APR):        5
    alone                                1
    followed by radiotherapy             3
    followed by chemoradiation           1
    Radiation                            1
    Chemoradiation                       14
    with concomitant 5FU-CDDP            11
    with concomitant 5FU-MMC             1
    with other concomitant Chemo         2

\*liver metastasis

APR: abdominoperineal resection; CDDP: cisplatin; Chemo: chemotherapy; MMC: mitomycin C

Mutational spectrum {#s2_2}
-------------------

WES of 20 tumours and matched normal samples targeted 216320 exons in 23103 genes, for a total of 50.4 Mb of captured regions. On average, 62M reads were sequenced per sample and 96.2% aligned on the reference genome, among which 31.2% were identified as PCR duplicates. Overall, the mean depth of coverage of the targeted regions was 119X and 51% of the exome was covered by more than 100X. In the total of 20 treatment-naive anal carcinoma samples, WES identified 2396 somatic variants in 2049 genes: 660 (27.3%) synonymous variants, 1492 (61.6%) missense variants, 25 in-frame indels (1.0%) and 219 protein-truncating variants (9.0%), including 38 splicing variants, 61 frameshift indels, 116 nonsense variants and 4 stoploss variants. The average number of non-synonymous mutations was 75 per tumour, ranging from 25 to 182 variants per tumour. Mutational trinucleotide signature in the 20 ASCC as determined by approaches described in the Materials and Methods section is showed in Figure [1](#F1){ref-type="fig"}. The signature associated with age (signature 1A) was observed in all tested ASCC. After the signature associated with age, the more frequent mutational trinucleotide signature, observed in 12 out of 20 tested ASCC, was the signature associated with APOBEC ("apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like") family (signature 2), followed by signatures associated with POLE mutations (5 cases) and UV light exposure (2 cases).

![Mutational trinucleotide signatures in the series of 20 ASCCs\
Mutational trinucleotide signatures were determined by approaches described in the Materials and Methods section.^18^ Signature 1A (Age) is characterized by C\>T in ACG, CCG, GCG or TCG; signature 2 (APOBEC) by C\>T and C\>G in TCA or TCT ; signature 7 (UV) by C\>T in TCG; and signatures 10 (POLE mutation ) by C\>T in TCG and C\>A in TCT. Signature R2 is not validated.](oncotarget-09-464-g001){#F1}

Recurrent gene mutations {#s2_3}
------------------------

The 15 genes mutated in at least two tumours (≥10%) are described in Table [2](#T2){ref-type="table"}. The majority of mutations were confirmed using Sanger analysis. *PIK3CA* mutations were found in 5 (25%) of the 20 ASCC, corresponding to the classical somatic activating hot-spot mutations described in the COSMIC database of somatic mutations in cancer \[[@R16]\]. The three other genes the more frequently mutated were *FBXW7* (*n =* 3), *FAT1* (*n =* 3)*,* and *TRIP12* (*n =* 3). It is noteworthy that the *FBXW7* gene is a well-known gene frequently mutated in various histological types of cancer \[[@R17]--[@R19]\]. The three *FBXW7* mutations (2 missenses and 1 nonsense) were all referenced as recurrent mutations in COSMIC database \[[@R16]\]. The *FAT1* gene has been described as a tumour suppressor gene involved in Wnt/β-catenin signalling \[[@R20]\] and frequently mutated in SCCs \[[@R16], [@R21]\]. *TRIP12* is an ubiquination-related gene less frequently reported as mutated in cancers. Mutations of this gene were essentially described in gastric and colorectal cancer with microsatellite instability, but also in the cervix carcinomas \[[@R16], [@R22]\]. The comparison of the observed mutation frequencies of the genes *FAT1* and *TRIP12* in various common cancers is indicated in the [Supplementary Table 1](#SD1){ref-type="supplementary-material"}. The 11 other genes mutated in 2 of the 20 tumours (10%) were *PHLDA3, MCM4, TAGAP, ASXL1, MCC, CYLD, ZNF469, ZAK, NOTCH1, MLL3* and *DDX5*.

###### Frequently mutated genes in the series of 20 ASCCs

  --------------------------------------------------------------------------------------------------------------
  Gene           Chromosomal location   Number of mutated samples   \%   Mutations (*n*)
  -------------- ---------------------- --------------------------- ---- ---------------------------------------
  *PIK3CA*\      3q26.3                 5                           25   MS (5)\
  NM_006218                                                              exon10:c.1624G\>A:p.E542K\
                                                                         exon10:c.1624G\>A:p.E542K\
                                                                         exon10:c.1633G\>A:p.E545K\
                                                                         exon21:c.3140A\>T:p.H1047L\
                                                                         exon21:c.3062A\>G:p.Y1021C

  *FBXW7*\       4q31.3                 3                           15   NS(1), MS(2)\
  NM_033632                                                              exon8:c.1177C\>T:p.R393X\
                                                                         exon10:c.1435C\>G:p.R479G\
                                                                         exon9:c.1322G\>A:p.R441Q

  *FAT1*\        4q35                   3                           15   NS (2), MS (1)\
  NM_005245                                                              exon2:c.1882C\>T :p.R628X\
                                                                         exon11:c.9014C\>G:p.S3005X\
                                                                         exon2:c.440C\>T:p.P147L

  *TRIP12*\      2q36.3                 3                           15   MS(1), FS(1), NS(1)\
  NM_004238                                                              exon33:c.4783C\>T:p.R1595X\
                                                                         exon37:c.5462_5469del:p.1821_1823del\
                                                                         exon3:c.590C\>T:p.S197F

  *PHLDA3*\      1q31                   2                           10   MS(2)\
  NM_012396                                                              exon1:c.315C\>A:p.F105L\
                                                                         exon1:c.110G\>A:p.G37E

  *MCM4*\        8q11.2                 2                           10   FS(1), MS(1)\
  NM_005914                                                              exon8:c.977_978del:p.326_326del\
                                                                         exon7:c.793G\>A:p.A265T

  *TAGAP*\       6q25.3                 2                           10   MS(1), NS (1)\
  NM_054114                                                              exon10:c.1130C\>G:p.S377X\
                                                                         exon4:c.118G\>A:p.E40K

  *ASXL1*\       20q11                  2                           10   NS(2)\
  NM_015338                                                              exon11:c.1249C\>T:p.R417X\
                                                                         exon12:c.2593G\>T:p.E865X

  *MCC*\         5q21                   2                           10   MS(1), NS(1)\
  NM_002387                                                              exon9:c.1176G\>T:p.K392N\
                                                                         exon12:c.1469C\>A:p.S490X

  *CYLD*\        16q12.1                2                           10   MS(1), NS(1)\
  NM_015247                                                              exon11:c.1616G\>A:p.C539Y\
                                                                         exon12:c.1794C\>A:p.Y598X

  *ZNF469*\      16q24                  2                           10   MS(1), NS(1)\
  NM_001127464                                                           exon2:c.7453C\>T:p.Q2485X\
                                                                         exon2:c.4766C\>T:p.P1589L

  *ZAK*\         2q24.2                 2                           10   NS(1), MS(1)\
  NM_016653                                                              NM_133646:exon12:c.1052C\>T:p.S351L\
                                                                         NM_016653:exon13:c.1045C\>T:p.Q349X

  *NOTCH1*\      9q34.3                 2                           10   MS(2)\
  NM_017617                                                              exon23:c.3859C\>T:p.R1287C\
                                                                         exon6:c.976G\>A:p.G326S

  *MLL3*\        7q36.1                 2                           10   MS (1), NS(1)\
  NM_170606                                                              exon42:c.9638C\>G:p.S3213X\
                                                                         exon7:c.965A\>T:p.H322L

  *DDX5*\        17q21                  2                           10   MS (2)\
  NM_004396                                                              exon12:c.1251C\>G:p.D417E\
                                                                         exon5:c.496G\>A:p.D166N
  --------------------------------------------------------------------------------------------------------------

FS: frameshift indels, MS: missense variants, NS: nonsense variants

Microsatellite and chromosomal instability {#s2_4}
------------------------------------------

No MSI was observed in the 20 ASCC. The Figure [2](#F2){ref-type="fig"} illustrates the SCNA observed in the 20 tumours. The statistical analysis identified 6 regions with relevant gains and 8 regions with relevant losses of DNA copy number. Full arm chromosomal gains were observed in 1p (*n =* 4), 1q (*n =* 7), 3q (*n =* 7) and 8q (*n =* 3). In addition, focal gains were observed in 1p, 3q, 5p, 8q and 16p ([Supplementary Table 2](#SD1){ref-type="supplementary-material"}). The focal gain in 3q observed in 18 of 20 (90%) tumours affects the *PIK3CA* gene. *MYC* and *TERT* genes were also affected by focal gains in 8q and 5p observed in 55% and 40% of the tumours respectively (Figure [2](#F2){ref-type="fig"} and [Supplementary Table 2](#SD1){ref-type="supplementary-material"}). In addition, 4 well-known oncogenes showed focal amplifications (characterized as described in Material and methods section): *DDR2* (1q23.3; *n =* 1), *CCND1* (11q13; *n =* 3), *AKT2* (19q13.2; *n =* 2) and *MDM2* (12q14.3; *n =* 1). We validated the focal status of gene amplification (size \< 10Mb) for 2 tumours (focal amplification of *CCND1* for tumour T8 and focal amplifications of *DDR2, AKT2* and *MDM2* for tumour T16) using array comparative genomic hybridization ([Supplementary Figure 1](#SD1){ref-type="supplementary-material"}). Full arm chromosomal losses were observed in 3p (*n =* 3), 4p (*n =* 4), 4q (*n =* 2), 16q (*n =* 4) and Xq (*n =* 6). Focal deletions were also identified in 2q, 3p, 4p, 4q, 10q, 13q, and 16q in 35% to 45% of the tumours ([Supplementary Table 2](#SD1){ref-type="supplementary-material"}). Among them, deletions in 4q (*FAT1* and *FBXW7*) and 2q (*TRIP12*) affect genes that are frequently mutated in some cancer types, suggesting a tumour suppressor role of these ones (Table [2](#T2){ref-type="table"} and [Supplementary Table 2](#SD1){ref-type="supplementary-material"}). Allelic losses in 16q that contains the putative tumour suppressor gene *CYLD* were also observed in 9 of 20 (45%) tumours. A deletion of the *PTEN* locus in 10q was identified in 9 tumours, including the one harbouring a *PTEN* mutation. We observed biallelic inactivation (mutations + LOH) for 1 of the 3 *FAT1* mutated tumors, for 3 of the 3 *TRIP12* mutated tumors and for the 2 *CYLD* mutated tumors (Table [2](#T2){ref-type="table"}). We suggested that other biallelic inactivation of *FAT1, TRIP12* and *CYLD (*as well as *PTEN)* could occur through promoter methylation of these four genes in the tumours showing only monoallelic inactivation (only LOH without somatic mutation or only somatic mutation without LOH).

![Somatic copy number alterations in the series of 20 ASCCs\
Frequency of copy number gains (red) and losses (blue) in *x* axis, chromosome position in *y* axis. "?" indicates the absence of well characterized driver gene.](oncotarget-09-464-g002){#F2}

Other focal deletions involve tumour suppressor genes in 3p (*BAP1, FHIT, SETD2, MLH1, TGFBR2, CTNNB1* and *PBRM1*), 13q (*RB1*) and 11q22-q25 (*ATM*) without any mutations found in these genes. In addition, 5 homozygous deletions were identified for the following loci: *EED* (11q14.2-q22.3), *CHL1* (3p26.1), *STK11* (19p13.3), *LDB1* (10q14) and *RB1* (13q14.2).

DNA alterations in one primary tumour and its matched metastasis {#s2_5}
----------------------------------------------------------------

For one primary tumour (T11), we performed WES in its matched pre-treated metachronous metastasis (M11). Similar somatic genomic alterations were observed between the primary tumour and the metastasis, including mutational load (124 mutations *versus* 142 mutations, with 40 mutations in common), mutational signature and SCNA profiles, with an *EED* homozygous deletion (Figure [3](#F3){ref-type="fig"} and Figure [4](#F4){ref-type="fig"}). However, it is noteworthy that the metastasis M11 exhibited a mutation in the *KRAS* gene (G12S) that was not found in the primary tumour and a *PIK3CA* mutation (E542K) different from this observed in the primary tumour T11 (Y1021C). The mutational status (*KRAS* and *PIK3CA* genes) of the primary tumour (T11) and its matched metastasis (M11) was confirmed by Sanger analysis.

![Common genetic alterations by signalling pathways in the series of 20 ASCCs](oncotarget-09-464-g003){#F3}

![DNA alterations in one primary tumour (T11) and its matched metastasis (M11)\
(**A**) mutational load (number of mutations per tumour). (**B**) mutational signature as determined by approaches described in the Materials and Methods section. (**C**) Copy number analyses. The two different homologous chromosomes for each couple are showed using two different lines. Copy number gains are in red and copy number losses in blue.](oncotarget-09-464-g004){#F4}

Significant altered signalling pathways {#s2_6}
---------------------------------------

We integrated mutation and SCNA data to characterize genomic alterations in the most frequently altered signalling pathways in SCCs \[[@R8]\]. Among the SCNAs, only the focal amplifications and the homozygous deletion have been considered relevant. The 5 most frequently altered pathways were the PI3K/AKT/mTOR pathway with 12 of 20 tumours (60%) harbouring focal amplifications and/or homozygous deletions and/or mutations, followed by the chromatin remodelling (45%) and ubiquitin mediated proteolysis (UBP) (35%) pathways and those involved in cell cycle regulation (35%) and squamous cell differentiation (30%) (Figure [3](#F3){ref-type="fig"}). No gene of the RAS/MAPK signalling pathway was altered.

Alterations in the PI3K/AKT/mTOR pathway included activating mutations of *PIK3CA* and *MTOR*, inactivating mutations (or homozygous deletions) of *PIK3R1, PTEN* and *STK11* and focal amplification of *AKT2.* All these somatic events were mutually exclusive.

The UBP pathway was altered in 7 tumours with mutations in *TRIP12, FBXW7, KEAP1* and *CYLD*. In this UBP pathway, two genes less well known to be involved in human carcinogenesis were identified: *TRIP12* and *CYLD*. These two putative tumour suppressor genes were located in chromosome 2q and 16q respectively that were frequently deleted in our series (Figure [2](#F2){ref-type="fig"}).

The three other frequently altered pathways in our series were the squamous cell differentiation pathway, where the totality of somatic events (*FAT1, NOTCH1* and *HES5*) were also mutually exclusive, the cell cycle regulation (*CCND1, RB1, TP53, CDK4* and *MDM2*) and the chromatin remodelling pathways (*EED, LDB1, MLL3, ASXL1, ARID1A, NSD1, KDM6A, SETD2* and *HIST1H3B*).

Correlation between altered pathways and clinico-histological parameters {#s2_7}
------------------------------------------------------------------------

No significant association was found between the five mainly altered pathways and tumour differentiation status or recurrence (Figure [3](#F3){ref-type="fig"}), which might be due to the small number of samples tested.

It is noteworthy that the only HPV16 negative sample (T20) did not show any alteration of the PI3K/AKT/mTOR pathway but harboured a mutation of *TP53*, a gene rarely mutated in ASCC \[[@R10], [@R23]\].

DISCUSSION {#s3}
==========

Genomic characterization of ASCC is crucial to better understand molecular mechanisms involved in anal carcinogenesis and identify new therapeutic targets and predictive biomarkers of response to chemoradiation. The integration of HPV DNA in the human genome is recognised as the main cause of ASCC \[[@R24]\], through the interaction of E6 and E7 oncoproteins with tumour suppressor genes, but other somatic genomic alterations could be involved in this process \[[@R25]\]. Recently 2 exome-wide mutational analysis interestingly showed a similar mutational profile in matched pre-, post-chemoradiotherapy and metastatic ASCC samples \[[@R14]--[@R15]\]. In order to complete the characterization of ASCC genomic landscape and avoid the identification of genetic alterations that could be induced by radiation or chemotherapy, we performed WES in a homogenous cohort of 20 treatment-naive ASCCs with corresponding complete clinico-pathological data. Our cohort is representative of the overall ASCC population, with 95% of HPV16 positive tumours and a 20% rate of tumour relapse after radiation-based therapy.

Among the most frequently mutated genes identified in this present study, *PIK3CA* and *FBXW7* have been reported consistently with similar frequencies in previous studies, mostly limited to the analysis of a panel of genes and performed on heterogeneous ASCC samples \[[@R9]--[@R13]\]. As *PIK3CA* and *FBXW7* genes are significantly mutated in other HPV associated squamous cell carcinomas, they could act as driver events in this histological type of cancers.

We identified recurrent somatic mutations in *FAT1* (15%) and *TRIP12* (15%) genes that have not been previously reported in ASCC. The *FAT1* gene is implicated in the squamous cell differentiation and encodes a cadherin-like protein that is able to suppress cancer cell growth *in vitro* and *in vivo* by binding ß-catenin and antagonizing its nuclear localization. Recurrent somatic variants of *FAT1* have been identified in several cancers and particularly in squamous cell carcinomas \[[@R21], [@R26], [@R27]\]. The inactivation of *FAT1* via mutations has been demonstrated to activate Wnt signalling, tumorigenesis and cell invasiveness \[[@R21]\]. The second newly identified mutated gene *TRIP12,* codes for an E3 ubiquitin-protein ligase involved in ubiquitin mediated proteolysis (UBP) pathway and regulation of DNA repair. In normal cells, TRIP12 mediates ubiquitination and degradation of the isoform p19ARF/ARF of CDKN2A, a well-known tumour suppressor required for p53/TP53 activation under oncogenic stress. The alteration of TRIP12 promotes the degradation of ARF rendering cells unprotected from oncogenic stress \[[@R28]\]. Few mutations of *TRIP12* have been described in cancers and in particular in HPV related SCCs as only 0.5% and 1.5% of head an neck squamous cell carcinomas (HNSCC) and cervical squamous cell carcinomas (CSCC) tested were found mutated in the COSMIC database \[[@R16]\]. However, it was recently demonstrated that *TRIP12* is negatively regulated by HPV/p16-related protein and that the inhibition of *TRIP12* expression*,* via repression of DNA damage repair pathway, was associated with a radiosensitization in HPV-positive HNSCC cells and xenografts. Moreover, overexpression of TRIP12 was associated with poor survival in 18 patients with HPV-positive HNSCC \[[@R29]\] and also be a predictive biomarker of response to chemoradiation in ASCC.

We confirmed, as previously reported \[[@R10], [@R12], [@R14], [@R15]\], frequent PI3K/AKT/mTOR pathway alterations, with at least one altered partner in 60% of ASCC samples but, additionally, our data suggest a complete mutual exclusion of the different alterations affecting this pathway, which has to be taken with caution considering the small sample size of the series. The majority of the altered partners in the PI3K/AKT/mTOR pathway were identical to those reported by Chung *et al.* \[[@R12]\] and concerned *PIK3CA, PIK3R1, PTEN, STK11* and *AKT2*. This result is promising because PI3K/AKT/mTOR pathway alterations have been associated with clinical response to therapies targeting this pathway in other squamous cell or HPV-associated carcinomas \[[@R30]--[@R32]\].

Apart from PI3K/AKT/mTOR pathway, alterations of other pathways were observed in at least 30% of our cohort and concerned specifically chromatin remodelling (45%), cell cycle regulation (35%), UBP (35%), and squamous differentiation (30%) pathways. These alterations are common in many other SCCs and have been associated with potential clinical responses to targeted therapies. An alteration of other druggable targets involved in receptor tyrosine kinase signalling pathways was also observed in 15% of ASCC, concerning particularly *FGFR3*, *DDR2* and *FLT1* genes. These data, adding to those of Chung *et al.* \[[@R12]\] who described a number of alterations in genes involved in DNA damage pathway, chromatin remodeling, FGFR and ERBB signalling, suggest promising new targeted therapy approaches in ASCC.

It is noteworthy that the only HPV16 negative sample (T20) did not show any alteration of the PI3K/AKTmTOR pathway but harboured a *TP53* mutation. These mutations are rare in ASCC but are correlated with HPV16 negative status, resistance to chemoradiotherapy and a poor prognosis \[[@R10], [@R23]\]. We reported a global moderate rate of somatic genetic mutations in ASCCs, which is known to correlate with the production of neoantigens \[[@R33]\]. This should make us consider the evaluation of immunomodulatory agents in the treatment of the ASCCs showing high rate of somatic genetic mutations: 3 out of 20 tested ASCC showed a mutational load \>200 somatic mutations. It is noteworthy that these three patients did not show particular clinical characteristics, and did not show germline or somatic mutation either of the gene POLE, or of one of the genes involved in DNA mismatch repair (MMR) or in homologous recombination deficiency (HRD).

In this regard, promising results have been recently reported in metastatic ASCC with the programmed death-1 (PD-1) immune checkpoint inhibitor nivolumab, in a phase 2 study \[[@R34]\]. Moreover, Mouw *et al.* recently described a significant and durable response to the anti-PD-1 antibody pembrolizumab in a metastatic ASCC patient whose tumour harbored a high mutational burden and neoantigens.

Based on the classification of Alexandrov *et al.* \[[@R35]\], we identified in our cohort a recurrent mutational trinucleotide signature, observed in 100% of tested ASCC, which was reported to be associated with age. This result is concordant with our population of patients containing a majority of elderly females with a long-term history of HPV infection. The second more frequently signature (60%) was associated with APOBEC cytosine deaminase activity, which has recently emerged as a significant mutagenic factor in human cancer and more particularly in HPV-induced cancer \[[@R36]\].

The WES analysis of one primary tumour and matched metastasis (T11-M11) in our series showed similar mutational load, mutational signature and SCNA profiles but revealed a different gene mutation status between the primary tumour and the metastasis, suggesting a tumour heterogeneity as this phenomenon was already observed in samples from different tumour sites in a previous study \[[@R10]\].

In conclusion, the WES analysis performed in our study extends knowledge of the genomic landscape of ASCC highlights the high frequency of *PIK3CA* and *FBXW7* mutations in non pre-treated primary tumours and reports the presence of new recurrently mutated genes that have not been previously described in ASCC, such as *FAT1* and *TRIP12*. The combined analysis of somatic mutations and copy number alterations reveals the presence of recurrent alterations of the PI3K/AKT/mTOR pathway, including mutations, homozygous deletions or amplifications, in 60% of the tumours and many other altered genes involved in druggable signalling pathways. The high somatic mutation burden found in some tumours, suggesting an elevated neoantigen load could also predict sensitivity of ASCC to immunotherapy. These results are obviously limited by the small sample size of the study and need to be confirmed in a larger series but they suggest promising new therapeutic approaches and bring new insights in the treatment of ASCC.

MATERIALS AND METHODS {#s4}
=====================

Sample collection {#s4_1}
-----------------

Human samples from ASCC and matched adjacent normal anal tissues were collected and frozen at diagnosis in the Institut Curie. The adjacent normal tissues were analysed and confirmed without dysplastic component by our referent pathologic team. All biopsy tissues were residual specimens collected after initial diagnosis (from anal tumour or peripheral lymph node tissue). No patient received previous treatment (treatment-naive tumour samples). All the tumour samples were macrodissected to achieve a maximal neoplastic cellularity (more than 50%). All adjacent control samples were confirmed to be free of tumour cells. For patients without adjacent normal adjacent tissue, a peripheral blood sample was collected to extract germline DNA. This retrospective study was reviewed and approved by the Ethics Committee of the Institut Curie (No. A10-024). According to French regulations, patients were informed of research performed with the biological specimens obtained during their treatment and did not express opposition. Clinical and biological data were collected for each patient. We also analysed an additional tumour sample corresponding to a metachronous (occurred 10 months after CRT) and distant peritoneal metastasis (M11) matched to the primary ASCC (T11), which was treated with systemic chemotherapy.

Whole exome sequencing analysis {#s4_2}
-------------------------------

The WES analysis was performed on paired DNA samples (tumour and matched normal control DNA). The coding sequences from individual libraries for each sample were captured using the SureSelect version 5.0 human All Exome kit (Agilent Technologies), according to the manufacturer's protocols. Captured DNA libraries were then sequenced using the Illumina HiSeq 2500 Genome Analyzer, yielding 200 (2 × 100) base pairs from the final library fragments. Raw data were deposited on the NCBI SRA (Sequence Read Archive) database (<https://www.ncbi.nlm.nih.gov/sra>), under series accession number SRP119025.

Detection of somatic mutations {#s4_3}
------------------------------

After a quality control of the FastQ data using FastQC (v0.10.1, Babraham Institute), sequenced reads were aligned to the hg19 human reference genome using Burrows-Wheeler Aligner BWA (v0.6.2, 1 mismatch allowed in the 22bp-seed, a maximum of 4 differences to the reference in the whole read and 1 alignment reported per read (Li Bioinformatics 2009) and PCR duplicates were quantified and removed using Picard Tools (v1.97, <http://broadinstitute.github.io/picard>). Finally, only alignment intersecting the targeted sequence (Agilent SureSelect V5) were and the overall quality of the targeted regions was assessed using BedTools (v2.17.0) (Quinlan Bioinformatics 2010).

VarScan2 (v2.3.6) was then used to call both Single Nucleotide Variation (SNVs) and small insertions/deletions (indels) predicted as present in the tumours and not in their matched normal control \[[@R37]\]. Only reads having a mapping quality higher than 20 and bases having a base quality higher than 17 were considered in the analysis. Somatic SNV was validated only when the following criteria were met: 1) it was identified by more than distinct pairs; 2) the number of distinct tags containing a particular mismatched base was higher than 5% of the total distinct tags in the tumour sample. The estimated neoplastic cell proportion was taken into account in the analysis. ANNOVAR (10/2013 version) was then used to annotate variants with the following databases: NCBI refGene, 1000 Genomes project frequencies, ESP project (Exome Sequencing Project) frequencies and COSMIC database \[[@R38]\]. Mutation function importance were predicted using SIFT, PolyPhen2 and MutationTaster. In order to prioritize the variants, only those present in the coding or splicing sites in the tumour have been considered relevant. The synonymous variants were analysed separately to identify any recurrence or impact on splicing assessed with MaxEntScan algorithm \[[@R39]\]. Because of the limited numbers of samples available for our study, a simple enumeration was realized to analyze the data for significantly mutated genes. Mutational trinucleotide signatures were obtained using the computational framework developed by Alexandrov *et al.* and both a homemade script and the R Package (R Core team, 2015) deconstructSigs \[[@R35], [@R40]\]. In order to best reconstruct the mutational profile of the tumours, an iterative approach was performed to determine the weights to assign to each signature. To this effect, raw trinucleotide counts were normalized by the number of times each trinucleotide context is observed in the human exome.

Sanger sequencing validation {#s4_4}
----------------------------

A total of 34 relevant somatic SNVs and indels identified by WES were verified by Sanger sequencing.

Detection of somatic copy number alterations {#s4_5}
--------------------------------------------

From the WES analysis, somatic copy number alterations (SCNA) in the tumour compared to the normal sample were detected using the R package (R Core team, 2015) Sequenza (v2.1.0) \[[@R41]\]. Sequenza uses read depth as well as B-allele ratio (BAF) of variants found in both germline/tumour samples to estimate the allele-specific copy number variations and the optimal ploidy and tumour cellularity, after a GC percentage correction.

Homozygous deletion and focal amplification events were characterized using FACETS (v0.5.0) that uses default parameters and a number of 50 iterations per model to obtain convergence \[[@R42]\]. FACETS estimates subclonal events which allows for a more accurate detection of homozygous deletion or focal amplification by discriminating them from low cellular fraction events. The mean log2 ratio in a chromosome region between 0.30 and 1.0 was classified as genomic gain, more than 1.0 (with a size \<10 Mb) as focal amplification, less than --0.30 as heterozygous deletion, and less than --1.0 (with a size \<5 Mb) as homozygous deletion. Relevant genes affected by a focal gain or deletion of a chromosomal region were selected using the IntOGen database \[[@R43]\].

Assessment of microsatellite instability status {#s4_6}
-----------------------------------------------

Microsatellite instability (MSI) status was performed on all samples subjected to WES using the MSI Analysis System (Promega, France), which is composed of 5-mononucleotide repeats (BAT-25, BAT-26, NR-21, NR-24 and MONO-27) to detect MSI and 2-pentanucleotide repeat loci to confirm identity between normal and tumour samples, following the manufacturer's instructions.

Human papilloma virus genotyping {#s4_7}
--------------------------------

HPV status has been assessed in the Pathology Department of Institut Curie. Total DNA, isolated from formalin-fixed tissue blocks, was used for HPV typing. Real-time PCR using Sybr^®^Green and specific primers for HPV16 and 18, was performed on a 7900HT Fast Real-Time PCR System (Applied Biosystems, Foster City, CA).
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APR

:   abdominoperineal resection

ASCC

:   anal squamous cell carcinoma

CGH

:   comparative genomic hybridization

CNA

:   copy number alteration

CSCC

:   cervical squamous cell carcinoma

CRT

:   chemoradiotherapy

HNSCC

:   head and neck squamous cell carcinoma

HPV

:   human papilloma virus

MSI

:   microsatellite instability

RT

:   radiotherapy

SCNA

:   somatic copy number alterations

SNV

:   single nucleotide variation

UBP

:   ubiquitin mediated proteolysis

WES

:   whole exome sequencing
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